COSMOS Pharmaceutical Corporation
CSMYFOTCHealthcare● Active
$41.20
+$4.14(+11.17%)
Market Cap$3.3B
P/E Ratio—
52W High$48.271
52W Low$37.06
COSMOS Pharmaceutical Corporation (CSMYF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSMYF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-05 | 2024-05 | 2023-05 | 2022-05 | 2021-05 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.042T | $0.024T | $0.033T | $0.033T | $0.039T |
| Depreciation & Amort. | $0.022T | $0.020T | $0.017T | $0.015T | $0.014T |
| Stock-Based Comp. | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| Change in Working Capital | ($0.009T) | $0.007T | $0.010T | ($0.001T) | ($0.011T) |
| Net Cash from Operations | $0.052T | $0.055T | $0.054T | $0.032T | $0.028T |
| Investing Activities | |||||
| Capital Expenditure | ($0.053T) | ($0.056T) | ($0.047T) | ($0.043T) | ($0.026T) |
| Purchases of Investments | $0.000T | $0.000T | ($0.001T) | ($0.001T) | ($0.001T) |
| Sales of Investments | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| Net Cash from Investing | ($0.055T) | ($0.057T) | ($0.049T) | ($0.044T) | ($0.019T) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.000T) | $0.000T | $0.000T | ($0.000T) | $0.000T |
| Dividends Paid | ($0.005T) | ($0.005T) | ($0.003T) | ($0.003T) | ($0.002T) |
| Debt Issued / Repaid | $0.015T | $0.015T | $0.008T | ($0.001T) | ($0.001T) |
| Net Cash from Financing | $0.008T | $0.009T | $0.003T | ($0.006T) | ($0.006T) |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.001T) | ($0.001T) | $0.008T | ($0.011T) | $0.002T |
| FCF Margin %(computed) | -0.08% | -0.07% | 0.94% | -1.50% | 0.25% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · JPY · T
Explore more COSMOS Pharmaceutical Corporation data
About COSMOS Pharmaceutical Corporation (CSMYF) Cash Flow Statement
COSMOS Pharmaceutical Corporation generated operating cash flow of $52.47B and free cash flow of ($0.86B) for 2025 — a FCF margin of -0.08%. Capital expenditure was ($53.33B).
Frequently asked questions
CSMYF · 4 questionsCOSMOS Pharmaceutical Corporation generated free cash flow of ($0.86B) for 2025, down 35.3% year-over-year.
CSMYF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10